Strides Pharma Science Financial Statements
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | (3.10) | 3.05 | (3.70) | 139 |
Op profit growth | 30.10 | (25) | 27.40 | 80.90 |
EBIT growth | 17.50 | (40) | 50 | 84.30 |
Net profit growth | (94) | 65.20 | 268 | (87) |
Profitability ratios (%) | ||||
OPM | 18.70 | 14 | 19.10 | 14.50 |
EBIT margin | 14.40 | 11.90 | 20.40 | 13.10 |
Net profit margin | 1.32 | 23.30 | 14.50 | 3.79 |
RoCE | 7.35 | 5.41 | 8.66 | 8.92 |
RoNW | 0.36 | 6.34 | 3.70 | 1.43 |
RoA | 0.17 | 2.65 | 1.54 | 0.65 |
Per share ratios () | ||||
EPS | 3.42 | 76.50 | 49.90 | 10.50 |
Dividend per share | 14 | 2 | 4.50 | 5 |
Cash EPS | (15) | 56.60 | 30.60 | (2.50) |
Book value per share | 282 | 275 | 307 | 297 |
Valuation ratios | ||||
P/E | 94.30 | 8.51 | 21.30 | 101 |
P/CEPS | (21) | 11.50 | 34.70 | (414) |
P/B | 1.14 | 2.36 | 3.45 | 3.54 |
EV/EBIDTA | 8.59 | 16.80 | 19.10 | 25.60 |
Payout (%) | ||||
Dividend payout | 295 | 2.71 | 10.10 | 7.49 |
Tax payout | (4.70) | (6.90) | (17) | (21) |
Liquidity ratios | ||||
Debtor days | 120 | 121 | 134 | 90.70 |
Inventory days | 88.50 | 82.60 | 89.10 | 52.30 |
Creditor days | (125) | (112) | (128) | (74) |
Leverage ratios | ||||
Interest coverage | (2.50) | (1.70) | (3.10) | (2.20) |
Net debt / equity | 0.79 | 0.90 | 1.23 | 1.22 |
Net debt / op. profit | 3.87 | 5.59 | 6.39 | 7.80 |
Cost breakup () | ||||
Material costs | (41) | (49) | (46) | (52) |
Employee costs | (16) | (15) | (15) | (12) |
Other costs | (24) | (22) | (19) | (21) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 2,752 | 2,839 | 2,755 | 2,862 |
yoy growth (%) | (3.10) | 3.05 | (3.70) | 139 |
Raw materials | (1,122) | (1,379) | (1,281) | (1,502) |
As % of sales | 40.80 | 48.60 | 46.50 | 52.50 |
Employee costs | (443) | (434) | (419) | (358) |
As % of sales | 16.10 | 15.30 | 15.20 | 12.50 |
Other costs | (671) | (630) | (528) | (588) |
As % of sales | 24.40 | 22.20 | 19.20 | 20.60 |
Operating profit | 516 | 397 | 527 | 414 |
OPM | 18.70 | 14 | 19.10 | 14.50 |
Depreciation | (174) | (154) | (126) | (131) |
Interest expense | (156) | (196) | (183) | (168) |
Other income | 53.10 | 94.10 | 161 | 92.10 |
Profit before tax | 240 | 140 | 379 | 207 |
Taxes | (11) | (9.70) | (63) | (42) |
Tax rate | (4.70) | (6.90) | (17) | (21) |
Minorities and other | (7) | 590 | 120 | (9.60) |
Adj. profit | 221 | 721 | 436 | 155 |
Exceptional items | (78) | (44) | (36) | (41) |
Net profit | 36.40 | 660 | 400 | 109 |
yoy growth (%) | (94) | 65.20 | 268 | (87) |
NPM | 1.32 | 23.30 | 14.50 | 3.79 |
- Switch to
-
Tabular DataGraph
Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 240 | 140 | 379 | 207 |
Depreciation | (174) | (154) | (126) | (131) |
Tax paid | (11) | (9.70) | (63) | (42) |
Working capital | 663 | 765 | 1,001 | 851 |
Other operating items | -- | -- | -- | -- |
Operating cashflow | 718 | 741 | 1,191 | 884 |
Capital expenditure | (1,014) | (200) | 2,357 | 1,745 |
Free cash flow | (296) | 542 | 3,548 | 2,629 |
Equity raised | 3,853 | 3,730 | 3,277 | 3,582 |
Investments | 549 | 588 | 1,082 | 711 |
Debt financing/disposal | 811 | 933 | 3,201 | 2,697 |
Dividends paid | 107 | 17.90 | 40.20 | 6.72 |
Other items | -- | -- | -- | -- |
Net in cash | 5,026 | 5,810 | 11,148 | 9,626 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Equity capital | 89.60 | 89.60 | 89.60 | 89.40 |
Preference capital | -- | -- | -- | -- |
Reserves | 2,438 | 2,559 | 2,374 | 2,659 |
Net worth | 2,527 | 2,649 | 2,464 | 2,749 |
Minority interest | ||||
Debt | 2,235 | 3,221 | 2,520 | 3,700 |
Deferred tax liabilities (net) | 121 | 484 | 667 | 58.60 |
Total liabilities | 4,951 | 6,507 | 5,805 | 6,641 |
Fixed assets | 2,512 | 4,101 | 3,597 | 3,760 |
Intangible assets | ||||
Investments | 549 | 702 | 588 | 1,525 |
Deferred tax asset (net) | 299 | 451 | 569 | 70.10 |
Net working capital | 1,353 | 737 | 747 | 957 |
Inventories | 783 | 874 | 552 | 733 |
Inventory Days | 104 | -- | 71 | 97.10 |
Sundry debtors | 932 | 987 | 882 | 996 |
Debtor days | 124 | -- | 113 | 132 |
Other current assets | 941 | 627 | 663 | 692 |
Sundry creditors | (825) | (891) | (712) | (780) |
Creditor days | 109 | -- | 91.60 | 103 |
Other current liabilities | (477) | (860) | (637) | (684) |
Cash | 237 | 517 | 303 | 329 |
Total assets | 4,951 | 6,507 | 5,805 | 6,641 |
- Switch to
-
ConsolidatedStandalone
Particulars ( Rupees In Crores.) | Sep-2020 | Jun-2020 | Mar-2020 | Dec-2019 | Sep-2019 |
---|---|---|---|---|---|
Gross Sales | 794 | 782 | 619 | 732 | 715 |
Excise Duty | -- | -- | -- | -- | -- |
Net Sales | 794 | 782 | 619 | 732 | 715 |
Other Operating Income | -- | -- | -- | -- | -- |
Other Income | 40.80 | 57.20 | 22 | 27.90 | 127 |
Total Income | 834 | 839 | 641 | 760 | 842 |
Total Expenditure ** | 662 | 648 | 772 | 574 | 610 |
PBIDT | 173 | 191 | (131) | 187 | 232 |
Interest | 36.90 | 36.90 | 40.30 | 39.60 | 40.40 |
PBDT | 136 | 154 | (172) | 147 | 191 |
Depreciation | 52.80 | 49.10 | 45.30 | 43.50 | 42 |
Minority Interest Before NP | -- | -- | -- | -- | -- |
Tax | 7.67 | 6.81 | (12) | 8.11 | 16.10 |
Deferred Tax | (1.60) | (3.50) | 1.21 | 3.19 | (8.70) |
Reported Profit After Tax | 77 | 102 | (207) | 92.30 | 142 |
Minority Interest After NP | (4) | (1.70) | (2.60) | (1.60) | (0.80) |
Net Profit after Minority Interest | 81 | 104 | (204) | 93.90 | 143 |
Extra-ordinary Items | 11.70 | 42 | (169) | 13.90 | 73.90 |
Adjusted Profit After Extra-ordinary item | 69.30 | 61.60 | (35) | 80 | 68.80 |
EPS (Unit Curr.) | 9.03 | 11.60 | (23) | 10.50 | 15.90 |
Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
Dividend (%) | -- | -- | -- | -- | -- |
Equity | 89.60 | 89.60 | 89.60 | 89.60 | 89.60 |
Public Shareholding (Number) | -- | -- | -- | -- | -- |
Public Shareholding (%) | -- | -- | -- | -- | -- |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
PBIDTM(%) | 21.80 | 24.50 | (21) | 25.50 | 32.40 |
PBDTM(%) | 17.10 | 19.70 | (28) | 20.10 | 26.70 |
PATM(%) | 9.70 | 13 | (33) | 12.60 | 19.80 |